On Wednesday, Exact Sciences (NASDAQ:EXAS) Corporation (NASDAQ:EXAS) maintained its Buy rating and $80.00 price target according to a report by TD Cowen. The reaffirmation follows the company's announcement of a 25% price increase for its Cologuard (CG) Plus product. The price hike was presented at the annual Clinical Lab Fee Schedule (CLFS) meeting held on Tuesday.
Exact Sciences is seeking the price adjustment based on the enhanced performance and cost benefits of CG Plus, which is expected to launch in 2025. According to TD Cowen, the new price does not yet reflect in their forecasts, but the product is anticipated to be a significant growth driver due to improved test performance and lower cost of goods sold (COGS).
The analyst from TD Cowen highlighted that the potential price increase for Cologuard Plus would offer a very notable benefit to Exact Sciences. Earlier in the week, the firm named Exact Sciences as its Best Small/Midcap Idea, signaling strong confidence in the company's growth prospects.
The Cologuard test is a non-invasive screening option for colorectal cancer. The introduction of CG Plus aims to build on the success of the original Cologuard test by offering better performance, which is likely to lead to higher testing volumes upon its release.
Exact Sciences has not yet publicly commented on the potential financial impact of the proposed price increase for CG Plus. The company's stock performance will continue to be watched closely by investors as the 2025 launch date for the product approaches.
In other recent news, Exact Sciences Corporation has been under the spotlight with several noteworthy developments. BTIG, a renowned financial services firm, has revised its price target for the company from $80 to $70, maintaining a buy rating. This adjustment follows a series of executive departures, including the company's Chief Commercial Officer, Everett Cunningham, who decided to join Illumina (NASDAQ:ILMN) for personal and professional reasons.
Exact Sciences is expected to provide updates that could influence its trajectory. Investors are particularly interested in the company's upcoming second-quarter earnings call, where a return to growth is anticipated. Additionally, the Cologuard-blood test readout is slated for fall, and there is potential FDA approval and possibly premium pricing for Cologuard Plus by the first quarter of 2025.
On the governance front, Exact Sciences' shareholders have elected three nominees to the Board of Directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2024. An advisory vote also approved the compensation paid to the company's named executive officers.
Meanwhile, Cathie Wood's ARK ETFs have been reducing their holdings in Exact Sciences. The ETFs have sold substantial shares of the company across several trading days, indicating a strategic shift in their investment approach. These recent developments underscore the dynamic nature of the investment landscape surrounding Exact Sciences.
InvestingPro Insights
As Exact Sciences Corporation (NASDAQ:EXAS) gears up for the launch of its Cologuard Plus product in 2025, the recent price increase announcement has put the spotlight on the company's growth potential. To provide a deeper understanding of the company's financial health and market performance, InvestingPro data indicates a market capitalization of $8.16 billion, with revenue growth over the last twelve months as of Q1 2024 at 15.21%. Despite these positive figures, the company's P/E ratio stands at -33.48, reflecting challenges in profitability, which is also echoed by the negative return on assets of -3.79%.
InvestingPro Tips suggest that analysts are cautious, with five analysts revising their earnings downwards for the upcoming period and not anticipating the company to be profitable this year. Additionally, the stock has experienced a significant downturn over the last six months, with a price total return of -45.31%. These metrics underscore the importance of strategic initiatives like the CG Plus for revitalizing investor confidence.
For investors seeking comprehensive analysis and additional insights, InvestingPro offers more tips on Exact Sciences. By using the coupon code PRONEWS24, you can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking valuable information to inform your investment decisions. Visit https://www.investing.com/pro/EXAS to explore further.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.